June 25, 2017 2:22 AM ET


Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pha...

Building D

Floor 3

35 Gatehouse Drive

Waltham, MA 02451

United States

Founded in 2005

32 Employees





Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $625.4K
President and Chief Operating Officer
Age: 45
Total Annual Compensation: $510.4K
Chief Medical Officer and Senior Vice President
Age: 65
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2016.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals, Inc. Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with Keytruda for the Treatment of Advanced Melanoma

Syndax Pharmaceuticals, Inc. announced results from the melanoma cohort of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago, Illinois. ENCORE 601 (NCT02437136) is a Phase 1b/2 trial evaluating the efficacy and safety of entinostat in combination with KEYTRUDA in melanoma patients whose disease had progressed despite prior treatment with anti-PD-1/PD-L1 therapies. Responses were seen both in patients who had, as well as those who had not, received prior treatment with YERVOY® (ipilimumab) in combination with an anti-PD-1 therapy, either (OPDIVO® (nivolumab) or KEYTRUDA). Of note, 1 patient with a confirmed PR converted from a PD-L1 negative, non-inflamed gene signature in a pre-treatment tumor biopsy to PD-L1 positive, inflamed gene signature post-treatment with the entinostat-KEYTRUDA combination. Correlative analyses of peripheral blood and tumor tissue biomarkers across the entire patient cohort are ongoing. The combination of entinostat and KEYTRUDA also appears to have a manageable toxicity profile, with 8 patients having a treatment emergent adverse event with severity of Grade = 3, and with 1 patient discontinuing treatment due to an adverse event (transaminitis that was deemed to be likely related to KEYTRUDA).

Syndax Pharmaceuticals to Present Data from Melanoma Study at 2017 ASCO Annual Meeting

Syndax Pharmaceuticals, Inc. has announced that it will present results from the melanoma cohort of the ongoing Phase II ENCORE 601 trial of entinostat in combination with KEYTRUDA, pembrolizumab, Merck's anti-PD-1, programmed death receptor-1, therapy at the American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago, Illinois. The Company recently reported that the first cohort of 13 melanoma patients who had progressed on or after prior immune checkpoint inhibitor therapy in ENCORE 601 met the pre-specified objective response criteria, with a minimum of 2 patients demonstrating a confirmed or unconfirmed objective response, to advance into the second stage of the trial. Data from the first cohort of patients indicate that 4 patients achieved an objective response (ORR) by irRECIST criteria (3 patients had a confirmed response; 1 patient had an unconfirmed response; 31% ORR, 95% CI: 9 - 61%). Of the 4 responders, 2 patients had stable disease (SD) and 2 patients had progressive disease (PD) as best response to their prior anti-PD-1 therapy prior to progressing, with a median duration on prior anti-PD-1 therapy of 4.9 months (range 2.7-12.5). Three patients remain on treatment, without progression, as of the data cutoff, 1 with a partial response (PR), and 2 with SD.

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017 11:00 AM

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017 11:00 AM. Venue: St. Regis Hotel, 2 East 55 Street, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

July 6, 2016
UCB Biopharma SPRL, UCB6352

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Syndax Pharmaceuticals, Inc., please visit www.syndax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.